Welcome to Paras Biopharmaceuticals Finland Oy
Paras Biopharmaceuticals Finland is an acclaimed enabler of biopharmaceutical manufacturing technologies for biosimilars and long therapeutic peptides. Our facilities in Finland are dedicated to the development and scale-up of recombinant products, and are also equipped for future GMP production. We offer optimized scale-up technologies for products that have the potential for clinical and commercial manufacturing.
Paras’ work revolves around three main streams
1. Biosimilars comprised of osteoporosis teriparatide, analog insulins and therapeutic fragment of mAbs
2. High value recombinant enzymes such as Enterokinase (and other enzymes in pipeline).
3. Innovative Oncology molecule in partnership with an esteemed research institution.
Paras Biopharmaceuticals offers a unique combination of technologies and facilities to deliver biosimilars for the following areas: Osteoporosis, Rheumatoid Arthritis, Diabetes and Oncology. Paras has successfully developed a Propriety Technology platform and is now expanding its IPR by filing PCT patents. Together with Diabrid, Noblecleav, Biomultifold (which results in high scale-up production) and other propriety technologies, Paras offers high yielding biosimilar technologies within biologic APIs.